|Title||Future perspective for potential Helicobacter pylori eradication therapies.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Debraekeleer, A., and H. Remaut|
|Date Published||2018 05|
Helicobacter pylori infection of the human stomach causes chronic inflammation and forms a major risk factor for the development of peptic ulcer disease and gastric cancer. Current standard eradication therapies use an acid-suppressing drug and two antibiotics, now frequently supplemented with bismuth. Declining eradication efficiencies, off-target effects of lengthy broad-spectrum antibiotic treatments and the desire of a more systematic eradication in asymptomatic H. pylori carriers to suppress gastric cancer incidence spur a search for an effective vaccine and alternative therapeutic options. Here, we review the current progress in the field, with an emphasis on narrow-spectrum or nonantibiotic therapeutics.
|Alternate Journal||Future Microbiol|
Future perspective for potential Helicobacter pylori eradication therapies.